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Prostate cancer is a very heterogeneous disease and its prognostic markers and 
oncogenes are under intensive research. Goal would be to assess patient’s unique 
”mutational fingerprint” and determine the best possible treatment for each individual 
cancer. 
This study examined the possible connection between prostate cancer and three proteins, 
mitochondrial aconitase (ACO2), malate dehydrogenase (MDH2) and nuclear Ku80 
(XRCC5). These were noticed to have an altered expression levels in prostate cancer in 
mass spectrometry analyses performed earlier. 
Study material consisted of previously obtained TMA-specimens with 502 primary 
prostatectomy (PP) and 148 hormone-refractory (HR) samples. These were stained 
immunohistochemically and observed with a virtual microscope. Possible protein 
expression was graded according to the staining intensity with a scale from 0 to 3. 
Of these proteins, ACO2 and MDH2 were noticed to have a statistically significant (p-value 
< 0.05) association with a proliferation marker Ki-67 which is expressed in actively dividing 
cells, including cancerous cells. This might suggest that these proteins are overexpressed 
in prostate cancer but more studies with larger sample sizes will be needed to verify the 
results.  
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1 INTRODUCTION 
 
 
References for this work were searched through Medline and PubMed -databases and 
with Google Scholar -search engine. References are original and review articles and 
websites, such as NCBI (National Center for Biotechnology Information). A textbook was 
also used for reference. 
 
1.1 Normal physiology of the prostate 
 
Robbins & Cotran Pathologic Basis of Disease, 9th edition (1) was used as a reference for 
chapters 1.1 and 1.2. Prostate is an organ situated retroperitoneally, encircling the neck of 
the bladder and urethra with the ejaculatory duct going through it and connecting with 
urethra inside the gland. Prostate can be divided anatomically and biologically into four 
distinct zones: periurethral, central, transitional and peripheral zone. Different pathologies 
arise often in distinct areas. For example, most benign hyperplasias develop in the 
transitional zone where they can obstruct the urethra and cause urinary retention and pain. 
On the other hand, carcinomas arise most often in the peripheral zone where they can be 
palpable during digital rectal examination. 
Histologically prostate contains glands, fibromuscular stroma between these glands and 
neuroendocrine cells. Glands are composed of two epithelial cell layers: cuboidal basal 
cells and columnar secretory cells. They are often large with papillary infoldings. 
Fibromuscular stroma has smooth muscle cells, fibroblasts and other cell types typical of 
glandular stroma. 
The normal function of the prostate is to secrete different enzymes, proteins and nutrients 
to the seminal fluid as it passes through the prostate during ejaculation. These different 
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molecules function, among other things, to liquefy the sperm and provide nutrients for the 
sperm cells. 
 
1.2 Pathogenesis of prostate cancer 
 
Great majority of cancers arising from the prostate are multifocal, gland-derived 
adenocarcinomas. Histologically carcinoma glands are only one cell layer thick with basal 
cell layer missing. Glands are often smaller than their benign counterparts and more 
circular. The nucleus in luminal cells is often large with one or several prominent nucleoli 
visible with normal light microscope. Mitotic figures are rare and general cell 
pleomorphisms aren’t that common. 
 
1.2.1 Mutational heterogeneity 
 
The course of prostate cancer varies greatly among individuals. To some, cancerous 
mutations never manifest as clinical symptoms and yet to others, cancer grows and 
spreads quickly sending metastases to other organs, particularly to bones in the case of 
prostate cancer. The role of genetic and epigenetic variations between different cancer 
genomes has been under intensive study as researchers have been trying to find 
correlations between mutations and clinical courses. A lot has been accomplished with a 
molecular classification of carcinomas according to the specific genetic aberrations. (2). 
There are a couple of validated germline mutations contributing to the prostate cancer risk. 
Only one is a definite prostate cancer predisposition gene, HOXB13. The other is BRCA2, 
which is associated with breast and ovarian cancer too. (2). 
The most common somatic mutation specific to prostate cancer is a fusion of an androgen-
regulated promotor area with an E26 transformation-specific (ETS) family transcription 
factor. The most common form is TMPRSS2-ERG fusion. It is found in between 40-50 % 
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of tumor foci. Despite its large prevalence, its effect to tumor prognosis is uncertain. Nearly 
90 % of ETS-fusions are of ERG-type. (3). Other common possibilities are ETV1, ETV4, or 
FLI1 (4). 
DNA-copy number alterations are also common in prostate cancer. Somatic point 
mutations on the other hand aren’t that prevalent (5). The genes mutated most often in 
prostate cancer are SPOP, TP53-deletion, FOXA1-amplification and PTEN-deletion. M. 
Loda et al. (4) found that 74% of 333 prostate cancer tumors could be subdivided to seven 
roughly distinct molecular classes: fusions involving (1) ERG, (2) ETV1, (3) ETV4 or (4) 
FLI1 or mutations in (5) SPOP, (6) FOXA1 or (7) IDH1. Especially SPOP mutations and 
chromosomal fusions have been found to be mutually exclusive. (4,5). 
 
1.2.2 The Role of androgens 
 
Androgens, especially dihydrotestosterone (DHT) have long been known to control critical 
cell survival and growth in prostate tissue. Type 2 5α-reductase, mostly in stromal cells, 
converts testosterone from the blood to DHT which binds to nuclear androgen receptor 
(AR) in the glandular cells and enables the transcription of androgen-dependent genes. 
(1). 
In prostate cancer, the dependence on androgens persists. Standard of care for locally 
advanced or metastasised carcinoma has long been chemically or surgically induced 
castration where circulating testosterone levels drop dramatically. Tumor often shrinks and 
stops advancing, but in most cases, it resurfaces with an acquired resistance to this 
androgen deprivation therapy (ADT). This malignancy is called a castration-resistant 
prostate cancer (CRPC) or hormone-refractory (HR) cancer. (6). 
Common mutations leading to castration-resistance include AR amplification as well as 
mutations in proteins that physically interact with the AR, such as FOXA1, MLL2, UTX and 
ASXL1. These proteins function as epigenetic modifiers and co-factors, for example MLL2 
encodes a histone methyltransferase which affects the expression of androgen receptor. 
(7). 
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1.3 Diagnosis and biomarkers in prostate cancer 
 
Essential part of the prognosis and treatment of prostate cancer is the early discovery of 
the disease. Biomarkers play a key role here as they are the means to acquire information 
from the tissues with minimal intervention. PSA has been the golden standard for 
diagnosing prostate cancer for over 25 years. It is however, not without its flaws; PSA 
levels rise in many common non-cancerous situations like inflammation and benign 
prostate hyperplasia. This leads to over-diagnosing and unnecessary prostate biopsies 
and because of these, psychological stress, loss of bodily function and pain ensues. (3). 
Thus, it is important to find more potent biomarkers with better sensitivity and specificity.  
Many promising candidates have emerged like urinary tests for TMPRSS2-ERG fusion 
and PCA3-overexpression. Other interesting possibilities are for example testing for 
circulating tumor cells and exosomes from the blood. These new methods are still used in 
conjunction with PSA but they provide enhanced positive and negative predictive values 
compared to PSA-test alone. (8). 
 
1.4 The epidemiology of prostate cancer 
 
Prostate cancer is the most common cancer diagnosed with men in developed countries 
with over 750 000 new cases annually. Worldwide there are estimated to be more than a 
million new cases and over 300 000 deaths every year as of 2012. (9). Statistics 
conducted in the United States show that prostate cancer accounts for 29% of all cancers 
diagnosed with men there (10). 
Age, ethnic background and family history are the most important risk factors in prostate 
cancer. People with African descent have the highest incidence, Asian men the most 
infrequent and Caucasians are in between. Cancer of the prostate, like majority of 
cancers, is typically a disease of older individuals, over 60 years most often. Positive 
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family history of the disease increases the risk for first degree relatives 2 to 4 times higher 
than that of the general population. (1,2,4). 
 
1.5 XRCC5, MDH2 and ACO2 in prostate cancer 
 
Mass spectrometry studies performed earlier showed that two mitochondrial proteins, 
aconitase (ACO2) and malate dehydrogenase (MDH2), and one nuclear DNA-repair 
protein, Ku80 (XRCC5) were having an altered expression levels in prostate cancer. This 
follow-up study aims to verify these expression level deviations using primary 
prostatectomy and castration resistant prostate cancer samples. 
 
1.5.1 ACO2 
 
Aconitase has a crucial part in a cell’s energy metabolism. It catalyses the conversion from 
citrate to iso-citrate, the second reaction in the kreb’s cycle. (11,12). In prostate tissue, this 
enzyme is normally inhibited causing accumulation of citrate. This excess citrate is 
secreted into the prostatic fluid where it serves as a nutrient for the semen. (13,14). 
Zinc has a pivotal role in inhibiting m-aconitase activity. Prostate tissue accumulates the 
greatest amount of zinc in the whole body, a part of which is stored in cells and a part 
secreted into the prostatic fluid. (15). In prostate cancer, this zinc accumulation system 
does not work. The protein supposed to transfer zinc across the cell membrane (ZIP1) is 
downregulated and intracellular zinc levels drop as much as 70-80 %. Thus, m-aconitase 
can convert citrate to iso-citrate, continuing kreb’s cycle towards oxidative phosphorylation. 
This change provides much needed energy for the growing and dividing cancer cells. 
(13,15). 
One study found that there was no significant change in the amount of m-aconitase in 
cancer cells and concluded that the increase in m-aconitase activity is due to the ceasing 
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of inhibition by zinc (16). Expression levels of metabolic enzymes are often only slightly 
different in malignant tissues compared to normal cells so the difference is difficult to 
notice (14). 
 
1.5.2 MDH2 
 
Malate dehydrogenase catalyses the reversible reaction between malate and oxaloacetate 
in the mitochondria. The enzyme has a pivotal role in attending and controlling for example 
kreb’s cycle, amino acid synthesis and gluconeogenesis. It is controlled allosterically by 
citrate. (17,18). 
Recent studies have found MDH2 to be over-expressed in uterine cancer as well as in 
prostate cancer. Suggestions as to how malate dehydrogenase acts in cancer have not yet 
been conclusive but over-expression is thought to improve on the energy status of the cell 
and thus provide fuel for mitosis and for example to remove cytostatics from the cancer 
cell. (19,20). MDH2 and ACO2 have both been found to affect the rate of mitosis (21). 
 
1.5.3 XRCC5 
 
Ku80 is in fact part of a heterodimer protein with a Ku70 counterpart. Together they unite 
with the DNA-PKcs (DNA protein kinase catalytic subunit) to form DNA-PK. Ku is an 
important factor in the non-homologous end joining (NHEJ) which repairs one of the most 
harmful damages to DNA, double-strand breaks (DSB). Ku finds the splitted DNA-strands 
and attaches to them making it possible for other enzymes to join in and begin repairing 
the DNA. (22,23). Inability to fix DSBs leads to genetic instability which in turn can cause 
apoptosis or oncogenic transformations (24). 
In addition to being an essential factor in NHEJ, Ku also functions as a transcriptional 
controller. Ku is part of transcription recycling and transcription factor recycling and also a 
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transcription factor for PSA promoter region. (25). Ku is traditionally expressed in the 
nucleus but it has also been found on cell membranes on certain cancer cell lines where it 
takes part in cell adhesion, migration and invasion (26). 
 
 
2 MATERIAL AND METHODS 
 
 
The study material consisted of previously obtained primary prostatectomy (PP) and 
hormone-refractory (HR) prostate tumor samples that had been processed to paraffin 
blocks using tissue microarray (TMA) technology. These blocks have then been sectioned 
into thin slices with a microtome and inserted on to individual microscope slides (27). The 
use of TMAs has been approved by the National Authority for Medicolegal Affairs. 
 
2.1 Immunohistochemical staining 
 
For each protein studied, the right dilution for the primary antibody and the proper buffer 
solution had to be tested before any final stains. All slides were eventually buffered in the 
Tris-EDTA buffer with pH 9. Dilutions for the primary antibodies were defined to be 1:500 
for ACO2, 1:300 for MDH2 and 1:8000 for XRCC5. 
The slides were stained automatically using Labvision’s Autostainer 480. N-Histofine® 
Simple Stain MAX PO (multi) detection reagent (anti-mouse and anti-rabbit) was used as a 
secondary antibody and a horseradish peroxidase (HRP) source. ImmPACT DAB 
Peroxidase (HRP) Substrate was used as a substrate for the HRP and it provided the dark 
brown stain used for scoring the possible expression intensity. Hydrogen peroxide (H2O2) 
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was used to minimize the background staining caused by endogenous peroxidase. 
Hematoxylin was used as a counterstain to visualize the nuclear morphology. 
 
2.2 Analyses with microscope 
 
After the staining protocol was finished, the slides were dehydrated with an increasing 
ethanol concentration and cleared with xylene. Coverslips were attached to the slides so 
that they could be more easily handled. 
The slides were scanned to the computer with Zeiss Axioskop40 microscope (Carl Zeiss 
MicroImaging, NY, USA) with 20x objective and a CCD colour camera (QICAM Fast; 
QImaging, Canada) and a motorized specimen stage (Märzhäuser Wetzlar GmbH, 
Germany). The slides were digitally examined using IIPZoomViewer- and JVSView-
programs. The intensity of the staining was graded from 0 to 3 with zero being no 
expression at all and 3 with the strongest staining. Figure 1 presents the staining 
differences using ACO2 expression as an example. 
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Figure 1. Examples of staining scores 1, 2 and 3 with ACO2, MDH2 and XRCC5 expression. 
First vertical column represents ACO2, second MDH2 and third XRCC5. 
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To keep the scoring consistent, the grading was done three times. Unclear, destroyed or 
non-cancerous specimens were excluded from the analyses. 
 
2.3 Statistical analyses 
 
The purpose of this study was to examine if aforementioned proteins (ACO2, MDH2 and 
XRCC5) have different expression levels in prostate cancer and if these expression 
differences are connected to common diagnostic markers in prostate cancer. Data for 
these variables has been previously collected. Analyses were done using Microsoft Office 
Excel 2016- and GraphPad Prism 6-softwares. 
Staining score was compared to PSA-score, Gleason-score, progression free months, 
survival until disease progression, age at diagnosis, tumor’s T-stage evaluated by a 
pathologist and Ki-67 expression level. T-stage and Ki-67 was studied also in CRPC-
specimens. Staining intensities between primary prostatectomy and CRPC-samples were 
also compared to see if statistically significant differences existed. 
One-way ANOVA’s Kruskal-Wallis test was used when comparing protein expression in 
primary prostatectomy and PSA, Gleason, progression free months, age at diagnosis and 
tumor’s T-stage in CRPC. T-test’s Mann Whitney test was used for tumor’s T-stage and Ki-
67 expression in primary prostatectomy samples and for Ki-67 expression in CRPC-
specimens. Mann-Whitney was also used when comparing scores between primary 
prostatectomy and CRPC-samples. 
Survival was also studied with Log-rank’s Mantel-Cox test. The endpoint was defined as 
the moment of disease progression to hormone-refractory type. 
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3 RESULTS 
 
 
The total number of samples stained was 1 665, of which 544 primary prostatectomy 
samples and 160 castration-resistant prostate cancer specimens were accepted to the 
subsequent analyses. More specific information about the distribution of the scores among 
the proteins and the individual number of samples are presented on table 1 for primary 
prostatectomy and on table 2 for CRPC-specimens. 
 
Table 1. Primary prostatectomy scores. 
 Expression score   
Proteins 0 1 2 3 Total Excluded 
XRCC5 0 (0 %) 30 (15 %) 105 (52 %) 66 (33 %) 201 (100 %) 125 
MDH2 29 (18 %) 59 (39 %) 50 (33 %) 15 (10 %) 153 (100 %) 173 
ACO2 13 (7 %) 49 (26 %) 92 (48 %) 36 (19 %) 190 (100 %) 136 
 
From table 1 it can be seen that expression score 2 was most common in XRCC5 and 
ACO2 whereas in MDH2 the score 1 was most prevalent. The portion of samples excluded 
was quite high which reduced the statistical strength and affected the significance of the 
results as we can see later. 
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Table 2. Castration-resistant prostate cancer scores. 
 Expression score   
Proteins 0 1 2 3 Total Excluded 
XRCC5 0 (0 %) 4 (12 %) 18 (55 %) 11 (33 %) 33 (100 %) 191 
MDH2 5 (8 %) 19 (30 %) 34 (54 %) 5 (8 %) 63 (100 %) 156 
ACO2 7 (11 %) 19 (30 %) 31 (48 %) 7 (11 %) 64 (100 %) 161 
 
The score 2 was clearly the most prevalent among all proteins in CRPC as visualised in 
table 2. The portion of samples excluded was even greater in CRPC than in prostatectomy 
samples. The differences in distribution between PP and CRPC scores were also studied. 
These results are presented as a graph in figure 2. No statistically significant relationship 
was found between scores given to PP or CRPC samples. 
 
 
Figure 2. Stacked column graphs comparing expression scores given to primary prostatectomy 
(PP) and hormone-refractory (HR) samples. 
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The scores given were a bit higher for hormone-refractory (HR) samples with XRCC5 and 
MDH2 but not in ACO2. Nevertheless, the differences were too small to be of statistical 
significance. 
Results comparing expression scores and common variables are presented on table 3 for 
XRCC5, on table 4 for MDH2 and on table 5 for ACO2 with means and standard 
deviations (SD) along with the P-values. Only Ki-67 expression in primary prostatectomy 
samples with ACO2 and MDH2 scores had a statistically significant result. 
 
Table 3. Results from XRCC5 
 Expression score  
Variables 1 2 3 P-value 
PSA (ng/ml) 14.09 ± 11.16 14.88 ± 11.06 12.19 ± 9.107 0.2821 
Progression 
free months 
90.76 ± 65.51 95.52 ± 74.51 100.4 ± 68.12 0.7603 
Age at 
diagnosis 
65.06 ± 5.648 62.81 ± 4.850 63.74 ± 4.331 0.2045 
Ki-67 CRPC 30.33 ± 10.26 13.13 ± 9.612 14.00 ± 8.106 0.0755 
Ki-67 PP 11.59 ± 12.25 6.435 ± 5.213 7.259 ± 4.577 0.0941 
T-stage PP 2: 23(79%), 3: 
6(21%) 
2: 105(67%), 3: 
35(33%) 
2: 46(70%), 3: 
20(30%) 
0.6015 
 
There were no significant results found when studying XRCC5 expression compared to 
common variables, although Ki-67 expression was almost statistically significant (P-value 
< 0.05). The pattern in Ki-67 expression was however divergent from the ones seen with 
ACO2 and MDH2 because the expression levels were higher on smaller protein 
expression scores. PSA’s and progression free months’ mean values increased with the 
expression scores but the differences were so small that they fit inside the standard 
deviations. 
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Table 4. MDH2 results 
 Expression score  
Variables 1 2 3 P-value 
PSA (ng/ml) 15.20 ± 12.68 19.51 ± 34.71 11.29 ± 4.433 0.9804 
Progression 
free months 
99.12 ± 70.50 90.44 ± 69.59 101.5 ± 62.92 0.6920 
Age at 
diagnosis 
62.62 ± 5.399 63.60 ± 4.967 62.12 ± 6.638 0.6258 
Ki-67 CRPC 14.94 ± 9.010 16.97 ± 10.28 0.5747 
Ki-67 PP 7.189 ± 6.677 12.17 ± 16.07 0.0362 
T-stage PP 2: 42(71%), 3: 
17(29%) 
2: 31(62%), 3: 
19(38%) 
2: 10(67%), 3: 
5(33%) 
0.4306 
 
With MDH2 the Ki-67 PP expression was statistically significant. The scores 2 and 3 were 
combined in Ki-67 expression because the amount of values was then more equal 
between score groups. The expression score was higher in primary prostatectomies with 
T-stage 2 than T-stage 3 but the difference was too small to be of significance. 
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Table 5. The results from ACO2 
 Expression score  
Variables 1 2 3 P-value 
PSA (ng/ml) 16.19 ± 14.81 15.84 ± 26.14 13.38 ± 9.299 0.7950 
Progression 
free months 
79.60 ± 66.76 96.17 ± 71.54 92.07 ± 67.44 0.5086 
Age at 
diagnosis 
63.08 ± 5.080 62.68 ± 5.724 64.14 ± 3.983 0.7344 
Ki-67 CRPC 19.12 ± 10.51 15.30 ± 9.968 0.2098 
Ki-67 PP 6.238 ± 4.838 10.24 ± 12.89 9.438 ± 8.628 0.0506 
T-stage PP 2: 36(73%), 3: 
13(27%) 
2: 63(68%), 3: 
29(32%) 
2: 23(64%), 3: 
13(36%) 
0.3407 
 
Ki-67 PP was almost significant with P-value 0.0506 when the scores 2 and 3 were 
handled separately. When the scores 2 and 3 were combined as was done with MDH2 
previously, the P-value became 0.0147 and the result was statistically significant. 
Gleason scores are presented on tables 6, 7 and 8 for XRCC5, MDH2 and ACO2, 
respectively. This is because Gleason grade was handled as a categorical variable with 
score distribution studied. T-stage was also handled as a categorical variable but these 
results are presented on tables 3, 4 and 5 nevertheless. 
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Table 6. The Gleason scores for XRCC5 in primary prostatectomy samples. 
 Expression score   
Gleason 1 2 3 Total P-value 
< 7 12 (14 %) 40 (49 %) 30 (37 %) 82 (100 %)  
7 15 (16 %) 52 (55 %) 27 (29 %) 94 (100 %)  
> 7  3 (13 %) 13 (57 %) 7 (30 %) 23 (100 %)  
     0.7519 
 
Table 7. The Gleason scores for MDH2 in primary prostatectomy samples. 
 Expression score   
Gleason 1 2 3 Total P-value 
< 7 20 (45 %) 17 (39 %) 7 (16 %) 44 (100 %)  
7 3 (43 %) 4 (57 %) 0 (0 %) 7 (100 %)  
> 7  17 (46 %) 13 (35 %) 7 (19 %) 37 (100 %)  
     0.7029 
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Table 8. The Gleason scores for ACO2 in primary prostatectomy samples. 
 Expression score   
Gleason 1 2 3 Total P-value 
< 7 19 (28 %) 35 (51 %) 14 (21 %) 68 (100 %)  
7 24 (28 %) 47 (54 %) 16 (18 %) 87 (100 %)  
> 7 5 (25 %) 9 (45 %) 6 (30 %) 20 (100 %)  
     0.8935 
 
There was no statistical difference between protein expression score and the Gleason 
grade given. The figures visualising the relationship between PP Ki-67 expression and 
ACO2 and MDH2 protein expression scores are presented in figure 2. 
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Figure 2. The relationship between Ki-67 expression and ACO2 and MDH2 scores in primary 
prostatectomy samples. Box represents the standard deviation with mean value as the line and the 
whiskers visualise maximum and minimum values. 
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Survival curves are presented on figure 3. Different expression levels are visualised in 
different colours. 
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Figure 3. Survival curves comparing disease progression in primary prostatectomy samples. 
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The survival curves did not differ significantly and median survival did not correlate to 
different protein expression levels. The results are analysed more in the following 
discussion-section.  
 
 
4 DISCUSSION 
 
 
These analyses conducted found a possible association with ACO2 and MDH2 with 
prostate cancer according to the stronger Ki-67 expression with higher staining grades. 
There have been many studies validating aberrant mitochondrial functions in prostate 
cancer (13,15,19,20), although some have suggested that for example the abnormal 
aconitase functions are connected to the faulty zinc metabolism (16). Metabolic enzymes 
are controlled by many intracellular pathways. Enzymes can therefore be more active even 
if their levels aren’t increased that noticeably (14).  
Aconitase and malate dehydrogenase are connected to each other as both affect the rate 
of mitosis (21) and malate dehydrogenase is controlled allosterically by citrate, the 
substrate for aconitase (18). Malate dehydrogenase has been found to be over-expressed 
in many cancers and it has many functions beneficial to the cancer like improving energy 
status and removing cytostatics from the cells (19,20). 
Ki-67 is a proliferation marker and it has a negligible expression in normal prostatic tissue. 
It is though active in cells going through cell cycle and hence very prominent in actively 
dividing cancer cells. (28). It has also been implicated as a good prognostic factor for the 
treatment decisions comparing radical or conservative therapy in prostate cancer (29). Ki-
67 has also been implicated as a promising prognostic factor for the metastasis and 
cancer specific death in prostate cancer (30,31). 
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This study consisted of previously obtained TMA slides which were stained with different 
antibodies. Statistical significance would probably have been higher with more undamaged 
specimens because a large part of the slides contained destroyed or missing spots. Larger 
specimen sizes will be needed for the full confirmation of the role of XRCC5, MDH2 and 
ACO2 in prostate cancer. To verify the results, several people should make the scoring to 
decrease its subjectivity. 
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